Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) will be posting its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.55 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Teva Pharmaceutical Industries stock opened at $7.83 on Tuesday. Teva Pharmaceutical Industries has a fifty-two week low of $7.46 and a fifty-two week high of $25.96. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The stock has a market cap of $7.97 billion, a P/E ratio of 2.80, a P/E/G ratio of 0.82 and a beta of 1.64. The firm has a 50-day moving average price of $8.49.

Several analysts have recently weighed in on the company. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Friday, July 5th. ValuEngine downgraded Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. UBS Group downgraded Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $22.00 to $12.00 in a research note on Tuesday, May 28th. Maxim Group reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald reduced their price objective on Teva Pharmaceutical Industries from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, June 12th. Six analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average target price of $14.87.

In other news, VP Notaristefani Carlo De sold 16,070 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the completion of the transaction, the vice president now directly owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sol J. Barer bought 111,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were acquired at an average cost of $8.98 per share, with a total value of $996,780.00. Following the completion of the purchase, the director now owns 115,942 shares in the company, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: Price to Earnings Ratio (PE)

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with's FREE daily email newsletter.